ArticleInvestigative and clinical urology2026
Risk of second primary cancer after radiotherapy for localized prostate cancer: A single-center Korean cohort study.
Article in Investigative and clinical urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe association between radiotherapy (RT) for localized prostate cancer and second primary cancer (SPC) remains controversial. We evaluated the incidence and risk of SPC after RT in a Korean single-center cohort. MATERIALS AND
methodsWe retrospectively analyzed 1,464 patients with localized prostate cancer treated between 2007 and 2018. SPC incidence was compared between RT and non-RT groups using Cox proportional hazards and Fine-Gray competing risk regression models. Standardized incidence ratios (SIRs) were calculated using age- and calendar year-specific incidence rates from the Korea Central Cancer Registry. Propensity score matching (PSM) was performed as a sensitivity analysis.
resultsDuring follow-up, 155 patients (10.6%) developed SPC. RT was associated with a higher risk of SPC compared with non-RT in multivariable Cox analysis (hazard ratio [HR] 3.43, 95% confidence interval [CI] 2.43-4.84) and Fine-Gray competing risk regression (subdistribution HR 3.32, 95% CI 2.36-4.67). SIR analysis demonstrated a markedly increased incidence of secondary bladder cancer in the RT group (SIR 11.51, 95% CI 6.83-18.20), whereas no increase was observed in the non-RT group. In contrast, colorectal cancer showed only a modest elevation after RT. In the PSM cohort, RT remained significantly associated with SPC in univariate analysis. Exploratory analyses according to RT modality and radiation field showed no significant differences.
conclusionsRT for localized prostate cancer was associated with an increased occurrence of SPC, particularly bladder cancer. These findings should be interpreted cautiously given the retrospective design and potential residual confounding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.